Review of studies of androgen treatment of female-to-male transsexuals: Effects and risks of administration of androgens to females

Journal of Sexual Medicine

Volumn 5, Issue 4, 2008, Pages 765-776

  Gooren, Louis J G ^a   Giltay, Erik J ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; ANDROGEN; C REACTIVE PROTEIN; ENDOTHELIN 1; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; INTERLEUKIN 6; KALLIKREIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TESTOSTERONE ESTER; VON WILLEBRAND FACTOR;

ANDROGEN THERAPY; ARTERIAL STIFFNESS; BLOOD PRESSURE MEASUREMENT; BODY FAT DISTRIBUTION; BODY MODIFICATION; BONE MASS; BREAST ATROPHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLITORIS HYPERTROPHY; DRUG SAFETY; ENDOMETRIAL DISEASE; ENZYME ACTIVITY; FEMALE; FEMALE TO MALE TRANSSEXUAL; HORMONAL THERAPY; HORMONE RESPONSE; HUMAN; INSULIN SENSITIVITY; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SODIUM RETENTION; SPATIAL DISCRIMINATION; SPEECH INTELLIGIBILITY; THROMBOSIS; VAGINA DISEASE; VIRILIZATION; WATER RETENTION;

EID: 41549149175     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2007.00646.x     Document Type: Review

References (91)

1. Wierman ME, Basson R, Davis SR, Khosla S, Miller KK, Rosner W, Santoro N. androgen therapy in women: An Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab 2006;91:3697-710.
2. Braunstein GD. Management of female sexual dysfunction in postmenopausal women by testosterone administration: Safety issues and controversies. J Sex Med 2007;4:859-66.
3. Kingsberg S. Testosterone treatment for hypoactive sexual desire disorder in postmenopausal women. J Sex Med 2007;4(3 suppl):227-34.
4. Gooren LJG. Androgen treatment of female-to-male transsexuals. In: Nieschlag E, Behre HM, eds. Testosterone, action, deficiency, substitution. New York: Springer Verlag Heidelberg; 1998: 529-44.
5. Zhou JN, Hofman MA, Gooren LJ, Swaab DF. A sex difference in the human brain and its relation to transsexuality. Nature 1995;378:68-70.
6. Kruijver FP, Zhou JN, Pool CW, Hofman MA, Gooren LJ, Swaab DF. Male-to-female transsexuals have female neuron numbers in a limbic nucleus. J Clin Endocrinol Metab 2000;85:2034-41.
7. Gooren L. The endocrinology of transsexualism: A review and commentary. Psychoneuroendocrinology 1990;15:3-14.
8. van Kesteren PJ, Gooren LJ, Megens JA. An epidemiological and demographic study of transsexuals in the Netherlands. Arch Sex Behav 1996;25:589-600.
9. Tsoi WF. The prevalence of transsexualism in Singapore. Acta Psychiatr Scand 1988;78:501-4.
10. De Cuypere G, Van Hemelrijck M, Michel A, Carael B, Heylens G, Rubens R, Hoebeke P, Monstrey S. Prevalence and demography of transsexualism in Belgium. Eur Psychiatry 2007;22:137-41.
11. Olsson SE, Moller AR. On the incidence and sex ratio of transsexualism in Sweden, 1972-2002. Arch Sex Behav 2003;32:381-6.
12. Weitze C, Osburg S. Transsexualism in Germany: Empirical data on epidemiology and application of the German Transsexuals' Act during its first ten years. Arch Sex Behav 1996;25:409-25.
13. Behre HM, Nieschlag E. Comparative pharmakinetics of testosterone esters. In: Nieschlag E, Behre HM, eds. Testosterone: Action, deficiency, substitution. 2nd edition, Vol. Chapter 11. Berlin: Springer Verlag; 1998:329-48.
14. Spinder T, Spijkstra JJ, Gooren LJ, Hompes PG, van Kessel H. Effects of long-term testosterone administration on gonadotropin secretion in agonadal female to male transsexuals compared with hypogonadal and normal women. J Clin Endocrinol Metab 1989;68:200-7.
15. Spinder T, Spijkstra JJ, van den Tweel JG, Burger CW, van Kessel H, Hompes PG, Gooren LJ. The effects of long term testosterone administration on pulsatile luteinizing hormone secretion and on ovarian histology in eugonadal female to male transsexual subjects. J Clin Endocrinol Metab 1989;69:151-7.
16. Bentvelsen FM, Brinkmann AO, van der Schoot P, van der Linden JE, van der Kwast TH, Boersma WJ, Schroder FH, Nijman JM. Developmental pattern and regulation by androgens of androgen receptor expression in the urogenital tract of the rat. Mol Cell Endocrinol 1995;113:245-53.
17. Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev 2003;24:313-40.
18. Wu FC, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 2003;24:183-217.
19. Giltay EJ, Gooren LJ. Effects of sex steroid deprivation/administration on hair growth and skin sebum production in transsexual males and females. J Clin Endocrinol Metab 2000;85:2913-21.
20. Giltay EJ, Gooren LJ. Effects of sex steroid deprivation/administration on hair growth and skin sebum production in transsexual males and females. J Clin Endocrinol Metab 2000;85:2913-21.
21. Giltay EJ, Toorians AW, Sarabdjitsingh AR, De Vries NA, Gooren LJ. Established risk factors for coronary heart disease are unrelated to androgen-induced baldness in female-to-male transsexuals. J Endocrinol 2004;180:107-12.
22. Lotufo PA, Chae CU, Ajani UA, Hennekens CH, Manson JE. Male pattern baldness and coronary heart disease: The Physicians' Health Study. Arch Intern Med 2000;160:165-71.
23. Futterweit W, Schwartz IS. Histopathology of the breasts of 12 women receiving long-term exogenous androgen therapy. Mt Sinai J Med 1988;55:309-12.
24. Sapino A, Pietribiasi F, Godano A, Bussolati G. Effect of long-term administration of androgens on breast tissues of female-to-male transsexuals. Ann NY Acad Sci 1990;586:143-5.
25. Anderson KE, Sellers TA, Chen PL, Rich SS, Hong CP, Folsom AR. Association of Stein-Leventhal syndrome with the incidence of postmenopausal breast carcinoma in a large prospective study of women in Iowa. Cancer 1997;79:494-99.
26. Balen A. Polycystic ovary syndrome and cancer. Hum Reprod Update 2001;7:522-5.
27. Slagter MH, Gooren LJ, Scorilas A, Petraki CD, Diamandis EP. Effects of long-term androgen administration on breast tissue of female-to-male transsexuals. J Histochem Cytochem 2006;54:905-10.
28. Somboonporn W, Davis SR. Testosterone effects on the breast: Implications for testosterone therapy for women. Endocr Rev 2004;25:374-88.
29. Futterweit W, Deligdisch L. Histopathological effects of exogenously administered testosterone in 19 female to male transsexuals. J Clin Endocrinol Metab 1986;62:16-21.
30. Pache TD, Hop WC, de Jong FH, Leerentveld RA, van Geldorp H, Van de Kamp TM, Gooren LJ, Fauser BC. 17 beta-Oestradiol, androstenedione and inhibin levels in fluid from individual follicles of normal and polycystic ovaries, and in ovaries from androgen treated female to male transsexuals. Clin Endocrinol (Oxford) 1992;36:565-71.
31. Hage JJ, Dekker JJ, Karim RB, Verheijen RH, Bloemena E. Ovarian cancer in female-to-male transsexuals: Report of two cases. Gynecol Oncol 2000;76:413-5.
32. Dizon DS, Tejada-Berges T, Koelliker S, Steinhoff M, Granai CO. Ovarian cancer associated with testosterone supplementation in a female-to-male transsexual patient. Gynecol Obstet Invest 2006;62:226-8.
33. Meyer WJ III, Webb, A, Stuart CA, Finkelstein JW, Lawrence B, Walker PA. Physical and hormonal evaluation of transsexual patients: A longitudinal study. Arch Sex Behav 1986;15:121-38.
34. Seeman E. Estrogen, androgen, and the pathogenesis of bone fragility in women and men. Curr Osteoporos Rep 2004;2:90-6.
35. Lips P, Asscheman H, Uitewaal P, Netelenbos JC, Gooren L. The effect of cross-gender hormonal treatment on bone metabolism in male-to-female transsexuals. J Bone Miner Res 1989;4:657-62.
36. Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C. Androgens and bone. Endocr Rev 2004;25:389-425.
37. Van Kesteren P, Lips P, Deville W, Popp-Snijders C, Asscheman H, Megens J, Gooren L. The effects of one-year cross-sex hormonal treatment on bone metabolism and serum insulin-like growth factor-1 in transsexuals. J Clin Endocrinol Metab 1996;81:2227-32.
38. Lips P, van Kesteren PJ, Asscheman H, Gooren LJ. The effect of androgen treatment on bone metabolism in female-to-male transsexuals. J Bone Miner Res 1996;11:1769-73.
39. van Kesteren P, Lips P, Gooren LJ, Asscheman H, Megens J. Long-term follow-up of bone mineral density and bone metabolism in transsexuals treated with cross-sex hormones. Clin Endocrinol (Oxford) 1998;48:347-54.
40. Melegos DN, Yu H, Ashok M, Wang C, Stanczyk F, Diamandis EP. Prostate-specific antigen in female serum, a potential new marker of androgen excess. J Clin Endocrinol Metab 1997;82:777-80.
41. Goh VH. Breast tissues in transsexual women-a nonprostatic source of androgen up-regulated production of prostate-specific antigen. J Clin Endocrinol Metab 1999;84:3313-5.
42. Obiezu CV, Giltay EJ, Magklara A, Scorilas A, Gooren LJ, Yu H, Howarth DJ, Diamandis EP. Serum and urinary prostate-specific antigen and urinary human glandular kallikrein concentrations are significantly increased after testosterone administration in female-to-male transsexuals. Clin Chem 2000;46:859-62.
43. Rittenhouse HG, Finlay JA, Mikolajczyk SD, Partin AW. Human kallikrein 2 (hK2) and prostate-specific antigen (PSA): Two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci 1998;35:275-368.
44. Diamandis EP, Yu H. Nonprostatic sources of prostate-specific antigen. Urol Clin North Am 1997;24:275-82.
45. Sauter ER, Ehya H, Babb J, Diamandis E, Daly M, Klein-Szanto A, Sigurdson E, Hoffman J, Malick J, Engstrom PF. Biological markers of risk in nipple aspirate fluid are associated with residual cancer and tumour size. Br J Cancer 1999;81:1222-7.
46. Zitzmann M, Nieschlag E. Testosterone levels in healthy men and the relation to behavioural and physical characteristics: Facts and constructs. Eur J Endocrinol 2001;144:183-97.
47. Van Goozen SH, Cohen-Kettenis PT, Gooren LJ, Frijda NH, Van de Poll NE. Gender differences in behaviour: Activating effects of cross-sex hormones. Psychoneuroendocrinology 1995;20:343-63.
48. Slabbekoorn D, van Goozen SH, Megens J, Gooren LJ, Cohen-Kettenis PT. Activating effects of cross-sex hormones on cognitive functioning: A study of short-term and long-term hormone effects in transsexuals. Psychoneuroendocrinology 1999;24:423-47.
49. Boersma EMM, Wood DA, Bassand JP, Simoons ML (eds.). Cardiovascular disease in Europe. Euro heart Survey and National Registries of Cardiovascular Diseases and Patient Management. Sophia Antipolis European Society of Cardiology; 2002.
50. Rosano GM, Sheiban I, Massaro R, Pagnotta P, Marazzi G, Vitale C, Mercuro G, Volterrani M, Aversa A, Fini M. Low testosterone levels are associated with coronary artery disease in male patients with angina. Int J Impot Res 2007;19:176-82.
51. Guzick DS. Cardiovascular risk in PCOS. J Clin Endocrinol Metab 2004;89:3694-5.
52. Laws A, Reaven GM. Insulin resistance and risk factors for coronary heart disease. Ballieres Clin Endocrinol Metab 1993;7:1063-78.
53. Legro RS. Polycystic ovary syndrome and cardiovascular disease: A premature association? Endocr Rev 2003;24:302-12.
54. Price JF, Lee AJ, Fowkes FG. Steroid sex hormones and peripheral arterial disease in the Edinburgh artery study. Steroids 1997;62:789-94.
55. Bernini GP, Moretti A, Sgro M, Argenio GF, Barlascini CO, Cristofani R, Salvetti A. Influence of endogenous androgens on carotid wall in postmenopausal women. Menopause 2001;8:43-50.
56. Phillips GB, Pinkernell BH, Jing TY. Relationship between serum sex hormones and coronary artery disease in postmenopausal women. Arterioscler Thromb Vasc Biol 1997;17:695-701.
57. Barrett-Connor E, Goodman-Gruen D. Prospective study of endogenous sex hormones and fatal cardiovascular disease in postmenopausal women. BMJ 1995;311:1193-6.
58. Wilson JD. Androgen abuse by athletes. Endocr Rev 1988;9:181-99.
59. van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxford) 1997;47:337-42.
60. Elbers JMH, Giltay EJ, Teerlink T, Scheffer MA, Asscheman H, Seidell JC, Gooren LJG. Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects. Clin Endocrinol 2003;58:562-71.
61. Gossl M, Lerman A. Endothelin: Beyond a vasoconstrictor. Circ 2006; 113: 1156-8.
62. Polderman KH, Stehouwer CDA, Van Kamp GJ, Dekker GA, Verheugt FWA, Gooren LJG. Influence of sex hormones on plasma endothelin levels. Ann Intern Med 1994;118:429-32.
63. Van Kesteren PJM, Kooistra T, Lansink M, Van Kamp GJ, Asscheman H, Gooren LJG, Emeis JJ, Vischer UM, Stehouwer CDA. The effects of sex steroids on plasma levels of marker proteins of endothelial cell functioning. Thromb Haemost 1998;79:1029-33.
64. Giltay EJ, Elbers JMH, Gooren LJG, Emeis JJ, Kooistra T, Asscheman H, Stehouwer CDA. Visceral fat accumulation is an important determinant of plasminogen activator inhibitor-1 levels in young, non-obese men and women: Modulation by cross-sex hormone administration. Arterioscler Thromb Vasc Biol 1998;18:1716-22.
65. Giltay EJ, Gooren LJG, Emeis J, Kooistra T, Stehouwer CDA. Oral, but not transdermal, administration of estrogens lowers tissue-type plasminogen activator levels without affecting its endothelial synthesis. Arterioscler Thromb Vasc Biol 2000;20:1396-403.
66. Toorians AW, Thomassen MC, Zweegman S, Magdeleyns EJ, Tans G, Gooren LJ, Rosing J. Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people. J Clin Endocrinol Metab 2003;88:5723-9.
67. Herrmann W. Significance of hyperhomocysteinemia. Clin Lab 2006;52:367-74.
68. Morris MS, Jacques PF, Selhub J, Rosenberg IH. Total homocysteine and estrogen status indicators in the Third National Health and Nutrition Examination Survey. Am J Epidemiol 2000;152:140-8.
69. Giltay EJ, Hoogeveen EK, Elbers JMH, Gooren LJG, Asscheman H, Stehouwer CDA. Effects of sex steroids on plasma total homocysteine levels: A study in transsexual males and females. J Clin Endocrinol Metab 1998;83:550-3.
70. Giltay EJ, Verhoef P, Gooren LJ, Geleijnse JM, Schouten EG, Stehouwer CD. Oral and transdermal estrogens both lower plasma total homocysteine in male-to-female transsexuals. Atherosclerosis 2003;168:139-46.
71. Marcucci R, Gori AM, Giannotti F, Baldi M, Verdiani V, Del Pace S, Nozzoli C, Abbate R. Markers of hypercoagulability and inflammation predict mortality in patients with heart failure. J Thromb Haemost 2006;4:1017-22.
72. Giltay EJ, Gooren LJ, Emeis JJ, Kooistra T, Stehouwer CD. Oral ethinyl estradiol, but not transdermal 17 beta-estradiol, increases plasma C-reactive protein levels in men. Thromb Haemost 2000;84:359-60.
73. von Eckardstein A, Kliesch S, Nieschlag E, Chirazi A, Assmann G, Behre HM. Suppression of endogenous testosterone in young men increases serum levels of high density lipoprotein subclass lipoprotein A-I and lipoprotein(a). J Clin Endocrinol Metab 1997;82:3367-72.
74. 2 cholesterol. Metabolism 1994;43:935-9.
75. Adams MR, Williams JK, Kaplan JR. Effects of androgens on coronary artery atherosclerosis and atherosclerosis-related impairment of vascular responsiveness. Arterioscler Thromb Vasc Biol 1995;15:562-70.
76. Elbers JM, Asscheman H, Seidell JC, Megens JA, Gooren LJ. Long-term testosterone administration increases visceral fat in female to male transsexuals. J Clin Endocrinol Metab 1997;82:2044-7.
77. Jacobeit J, Gooren, LJ, Schulte, HM. Long-acting intramuscular testosterone undecanaote for treatment of female-to-male transgender individuals. J Sex Med 2007 [Epub ahead of print].
78. Mueller A, Kiesewetter F, Binder H, Beckmann MW, Dittrich R. Long-term administration of testosterone undecanoate every 3 months for testosterone supplementation in female-to-male transsexuals. J Clin Endocrinol Metab 2007 [Epub ahead of print].
79. Eckardstein A, Wu FC. Testosterone and atherosclerosis. Growth Horm IGF Res 2003;13(A suppl):S72-84.
80. Safar ME, Czernichow S, Blacher J. Obesity, arterial stiffness, and cardiovascular risk. J Am Soc Nephrol 2006;17(2 suppl):S109-11.
81. Safar ME, Levy BI, Struijker-Boudier H. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circ 2003;107:2864-9.
82. Giltay EJ, Lambert J, Gooren LJ, Elbers JM, Steyn M, Stehouwer CD. Sex steroids, insulin, and arterial stiffness in women and men. Hypertension 1999;34:590-7.
83. McCredie RJ, McCrohon JA, Turner L, Griffiths KA, Handelsman DJ, Celermajer DS. Vascular reactivity is impaired in genetic females taking high-dose androgens. J Am Coll Cardiol 1998;32:1331-5.
84. Zitzmann M, Brune M, Nieschlag E. Vascular reactivity in hypogonadal men is reduced by androgen substitution. J Clin Endocrinol Metab 2002;87:5030-7.
85. Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. Endocr Rev 2007;28:463-91.
86. Polderman KH, Gooren LJG, Asscheman H, Bakker A, Heine RJ. Induction of insulin resistance by androgens and estrogens. J Clin Endocrinol Metab 1994;79:265-71.
87. Diamond MP, Grainger D, Diamond MC, Sherwin RS, Defronzo RA. Effects of methyltestosterone on insulin secretion and sensitivity in women. J Clin Endocrinol Metab 1998;83:4420-5.
88. Seidell JC, Bjorntorp P, Sjostrom L, Kvist H, Sannerstedt R. Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism 1990;39:897-901.
89. van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol 1997;47:337-42.
90. Gooren LJ, Bunck MC. Androgen replacement therapy: Present and future. Drugs 2004;64:1861-91.
91. Nieschlag E. Testosterone treatment comes of age: New options for hypogonadal men. Clin Endocrinol (Oxford) 2006;65:275-81.